A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

Table 4 Characteristics of studies comparing two dosage forms of mebeverine included in meta-analysis

Study	Treatment duration (wk)	Dosage		IBS subtype	Sex (F/M)	Mean age (yr)
		Meb 200 mg bid	Meb 135 mg bid			Meb 200 mg	Meb 135 mg
Gilbody et al[24] 2000	4-8	n = 92	n = 92	Abdominal pain predominant	142/42	34	32
Inauen et al[25] 1994	3	n = 24	n = 24	All subtype	36/12	43	37

Meb: Mebeverine.